Melanoma-associated antigen 3 peptide-HLA complex (MAGE-A3/HLA)

Melanoma-associated antigen 3 (MAGE-A3) is a prominent member of the cancer-testis antigen family, characterized by its restricted expression in the immune-privileged germ cells of the testis and its aberrant re-expression in a wide variety of solid and hematologic tumors. The therapeutic target is not the protein itself, but rather specific intracellularly processed MAGE-A3 peptides that are presented on the cell surface by Human Leukocyte Antigen (HLA) class I or II molecules. This peptide-HLA complex is recognized by the T-cell receptors (TCRs) of cytotoxic T-lymphocytes, making it a primary focus for TCR-engineered T-cell therapies (TCR-T), cancer vaccines, and bispecific T-cell engagers. In oncology, MAGE-A3 expression is often associated with advanced disease stages and poor prognosis in patients with melanoma and lung cancer. While MAGE-A3 is highly tumor-specific, clinical development has encountered significant hurdles, most notably severe off-target toxicities. These include fatal neurotoxicity caused by TCR cross-reactivity with MAGE-A12 expressed in the brain and cardiotoxicity due to unexpected recognition of the muscle protein Titin. Consequently, modern drug development for this target emphasizes high-precision TCR engineering and rigorous screening for cross-reactivity to ensure safety.

Other names

MAGE-A3 antigenMelanoma antigen family A 3Cancer/testis antigen 1.3CT1.3MAGE3MAGE-A3 peptide-MHC complex

T-cell receptor (TCR) binding and activation of cytotoxic T-lymphocytes to induce tumor cell lysis.